Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00147823
Other study ID # SUNY UMU IRB # 5130
Secondary ID
Status Completed
Phase N/A
First received September 1, 2005
Last updated June 4, 2015
Start date December 2004
Est. completion date December 2011

Study information

Verified date December 2013
Source State University of New York - Upstate Medical University
Contact n/a
Is FDA regulated No
Health authority United States: Institutional Review Board
Study type Interventional

Clinical Trial Summary

This is a prospective randomized study comparing Vitoss alone versus Vitoss with bone marrow aspirate in benign bone lesions.


Description:

Bone graft obtained from a patient's own bone (autogenous), usually around the pelvis, is currently considered the gold standard for bone grafting material. It provides a structural scaffold on which the patient's own bone may grow into (osteoconduction), growth factors that can stimulate healing (osteoinduction), and primitive cells (progenitors) that can stimulate bone formation directly (osteogenesis). It readily regains a blood supply from the surrounding tissues (revascularization) and is incorporated into the recipient site. However, there are significant disadvantages in the use of the patient's own bone graft including complications where the bone is taken from (donor site morbidity), limited availability and expense. For defects created by scraping (curettage) of non-cancerous (benign) bone lesions, a structural scaffold (osteoconduction) is generally considered the minimal necessary role that the graft material must serve to allow healing of the defect. Hence, human donor bone procured at the time of death (allografts) and synthetic bone fillers have been used as an alternative to the patient's own bone (autogenous bone graft).

The question that remains is whether additional growth factors that can stimulate bone formation (osteoinductive property) and/or cells that form bone directly (osteogenic property) facilitate healing of these defects when added to a material other than the patient's own bone graft source. In our experience with the use of the synthetic bone graft substitute ultraporous beta-tricalcium phosphate (TCP) (Vitoss, Orthovita, Inc.) over the last 3 years, the graft material, when combined with local blood alone, has performed well clinically but has persisted for a year or longer radiographically in some cases. Prolonged persistence of the graft material may serve as a potential stress riser, although we did not observe any untoward late effects in our published work. Several authors have studied the effects of composite grafts formed from a combination of bone graft substitutes and the patient's own bone marrow in animal models with promising results. There are no studies in the current literature evaluating the effects of healing in composite ultraporous beta-tricalcium phosphate and bone marrow aspirate (BMA) in defects after scraping of benign tumors (cavitary defects) in humans. The purpose of this study is to prospectively examine healing of cavitary defects treated with TCP alone versus those treated with TCP combined with BMA. Our hypothesis is that both graft resorption and trabeculation (radiographic measures of incorporation of the synthetic material by the native bone) will be more advanced at each time point in those patients that receive BMA plus TCP compared to those that receive TCP alone. Patients with any type of benign bone lesion indicated for surgical curettage would be offered inclusion in the study and followed for a minimum of 2 years post-operatively. Bone marrow aspiration would be obtained by a needle inserted through the skin (percutaneous aspiration) from the large bone of the pelvis (iliac crest) using a standard bone marrow aspiration needle. Patients with infection, bone marrow disorders, or other conditions that preclude use of supplementary the patient's bone marrow as well as those who prefer to use their own bone graft material (autograft) or donated human bone graft (allograft) alone would be excluded. Each patient will undergo radiographic evaluation of the lesion at 6 weeks, 3 months, 6 months, 1 year, 18 months and 2 years post operatively. At one time point (1 year) a computerized tomogram (CT) of the grafted region will be obtained for each patient. Two qualified, blinded, independent reviewers will evaluate the radiographs and CT scans for six criteria:

1. presence of graft within the soft tissues,

2. presence of a rim of radiolucency surrounding the grafted defect,

3. size/circumference of the rim of radiolucency,

4. resorption of graft material,

5. trabeculation through the defect and

6. persistence of graft material in the lesion.

Kappa statistics have shown good agreement for these parameters in our retrospective preliminary analysis of results for the TCP use without bone marrow over the first 2 years of its use by the PI.


Recruitment information / eligibility

Status Completed
Enrollment 63
Est. completion date December 2011
Est. primary completion date December 2011
Accepts healthy volunteers No
Gender Both
Age group N/A and older
Eligibility Inclusion Criteria:

- Patients with a benign bone lesion requiring surgical curettage

Exclusion Criteria:

- Patients with infection, bone marrow disorders, or other contraindications to use of supplemental bone marrow aspiration as well as those who prefer autologous or allogeneic graft material alone (without synthetic filler) would be excluded.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Device:
Vitoss Alone
Synthetic bone graft material
Vitoss with Bone Marrow Aspirate
Vitoss mixed with Bone Marrow aspirate

Locations

Country Name City State
United States SUNY Upstate Medical University Syracuse New York

Sponsors (2)

Lead Sponsor Collaborator
State University of New York - Upstate Medical University Orthovita d/b/a Stryker

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Bone Trabeculation Through the Defect (BT) Compared at 24 Months Bone trabeculation through the bone lesion at 24 months as determined with radiographs. There were several participants with incomplete follow up or incomplete radiographs. . 24 months No
Other Resorption of Graft Material (GR) Compared at 18 Months Percentage of graft material that is resorbed (disappears) from area of incorporation at 18 months. Participants were seen 18 month follow with radiographs to review resorption of graft material. There a several that had incomplete follow up or radiographs not taken. 18 months No
Other Bone Trabeculation Through the Defect (BT) Compared at 18 Months Bone trabeculation through the bone lesion at 18 months with reviewed with radiographs. There were several participants with incomplete follow up or incomplete radiographs. 18 months No
Other Resorption of Graft Material (GR) Compared at 12 Months Percentage of graft material that is resorbed (disappears) from area of incorporation at 12months. Participants were seen 12 month follow with radiographs to review resorption of graft material. There a several that had incomplete follow up or radiographs not taken. 12 months No
Other Bone Trabeculation Through the Defect (BT) Compared at 12 Months Bone trabeculation through the bone lesion at 12 months was reviewed with radiographs. There were several participants with incomplete follow up or incomplete radiographs. 12 months No
Other Resorption of Graft Material (GR) Compared at 6 Months Percentage of graft material that is resorbed (disappears) from area of incorporation at 6 months. Participants were seen 6 month follow with radiographs to review resorption of graft material. There a several that had incomplete follow up or radiographs not taken. 6 months No
Other Bone Trabeculation Through the Defect (BT) Compared at 6 Months Bone trabeculation through the bone lesion at 6 months was reviewed with radiographs. There were several participants with incomplete follow up or incomplete radiographs. 6 months No
Other Resorption of Graft Material (GR) Compared at 3 Months Percentage of graft material that is resorbed (disappears) from area of incorporation at 3 months. Participants were seen 3 month follow with radiographs to review resorption of graft material. There a several that had incomplete follow up or radiographs not taken. 3 months No
Other Bone Trabeculation Through the Defect (BT) Compared at 3 Months Bone trabeculation through the bone lesion compared at 3 months were reviewed with radiographs. There were several participants with incomplete follow up or incomplete radiographs. 3 months No
Other Resorption of Graft Material (GR) Compared at 6 Weeks Percentage of graft material that is resorbed (disappears) from area of incorporation at 6 weeks. Participants were seen 6 week follow with radiographs to review resorption of graft material. There a several that had incomplete follow up or radiographs not taken. 6 weeks No
Other Bone Trabeculation Through the Defect (BT) Compared at 6 Weeks Bone trabeculation through the bone lesion compared at 6 weeks were reviewed with radiographs. There were several participants with incomplete follow up or incomplete radiographs. 6 weeks No
Primary Resorption of Graft Material (GR) Compared at 24 Months Percentage of graft material that is resorbed (disappears) from area of incorporation, at 24 months .Participants were seen 24 month follow with radiographs to review resorption of graft material. There a several that had incomplete follow up or radiographs not taken. 24 months No
See also
  Status Clinical Trial Phase
Completed NCT03672513 - Short-term Supplementation, Bone Turnover and Antioxidant Status in Menopause N/A
Completed NCT00070681 - Outcomes of Sleep Disorders in Older Men Phase 3
Recruiting NCT03905174 - Massive Implants the Next Generation N/A
Completed NCT03050203 - Custom Pack in Spine Surgery N/A
Completed NCT00000466 - Postmenopausal Estrogen/Progestin Interventions (PEPI) Phase 3
Recruiting NCT03904914 - Thumb Ossification Composite Index (TOCI) to Predict Skeletal Maturity and Curve Progression in AIS
Completed NCT04608708 - 3D Analysis of Cemento-Osseous Lesions
Completed NCT02252679 - Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders
Completed NCT03633032 - Radiation-free Bone Imaging UTE MRI in Healthy and Diseased Patients N/A
Recruiting NCT03431727 - Acromegaly - Before and After Treatment
Completed NCT03072186 - Proposal for Intraoperative Administration of Intravenous Indocyanine Green to Evaluate Position of the Optic Canal, Position of the Internal Carotid Arteries, Tumor Vascularization, and Vessel Encasement in Endoscopic Endonasal Cranial Base Surgery N/A
Completed NCT03438123 - Data Collection Study for the Spectrum Dynamics Multi-purpose CZT SPECT Camera N/A
Recruiting NCT06116071 - Biomarkers Related to Bone in Pediatric Gaucher Disease
Not yet recruiting NCT05840003 - Image Quality: Ultra-Low Dose Scanner Versus Standard Dose Conventional Scanner for Thoraco-abdominopelvic Scans N/A
Withdrawn NCT04955652 - Evaluation of Alerts in Promoting Bone Densitometry Scans N/A
Recruiting NCT00270608 - How Does Early Age Life Style Affect Bone Strength and General Health Parameters at Middle Age? N/A
Active, not recruiting NCT00150163 - Odense Androgen Study: Study of Androgens, Body Composition, and Muscle Function in Danish Men N/A
Completed NCT00155961 - Odense Androgen Study in the Elderly Phase 1
Terminated NCT03802656 - Vertebral Body Tethering Treatment for Idiopathic Scoliosis N/A
Not yet recruiting NCT05802121 - Akkermansia Muciniphilia and Metabolic Side Effects of ADT Early Phase 1